Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Collaborating with Chemetics
January 2016
EDIT CONNECT

SHARING OPTIONS:

COPENHAGEN, Denmark—Nuevolution A/S and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have struck up a multitarget collaboration featuring Nuevolution’s proprietary Chemetics drug discovery platform. The companies will focus on the discovery and development of new medical entities for the treatment of oncological, infectious and inflammatory diseases, with Nuevolution applying its platform to discover and advance drug candidates against drug targets of interest to Janssen. Though no specific financial details were shared, Nuevolution stands to receive an upfront payment, research funding and milestone payments, if certain research, development and commercial milestones are reached, as well as royalty payments on net sales of commercialized products resulting from this deal.
 
“We are excited about entering into the extensive collaboration with Janssen,” said Alex Gouliaev, CEO of Nuevolution. “We are looking forward to an excellent working relationship with their dedicated research and development teams.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.